Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …

Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and
mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a …

Venous thromboembolism (VTE) is a frequent and potentially fatal complication in patients
with cancer. During the initial period after the thromboembolic event, a patient receiving …

Background Clinical guidelines suggest continuing anticoagulation therapy for> 6 months
for patients with active cancer and venous thromboembolism (VTE). However, data …

The concept of pulmonary embolism is evolving. Recent and emerging evidence on the
treatment of specific patient populations, its secondary prevention, long-term complications …

Management of cancer-associated thrombosis (CAT) is usually performed employing low
molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs). Low-intensity …

Background Incidence of and risk factors for bleeding in cancer patients with venous
thromboembolism (VTE) treated with apixaban are poorly described. Methods We analyzed …

Introduction In a recent interventional study of cancer patients with newly diagnosed venous
thrombosis (VT), we found a high risk of arterial thrombotic events (AT) during treatment with …

Background In the recent years, numerous studies on the optimal treatment and prevention
of cancer-associated venous thromboembolism (VTE) have been published, leading to …

One in two people will develop cancer at some point in their lives 1 and venous
thromboembolism (VTE) will complicate the clinical journey of one in 20 cancer patients. 2 …